EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Immune tolerance versus cancer surveillance: an ongoing challenge

Michael Agrez

Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014602

DOI: 10.1136/jitc-2025-014602 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.05.2026. Verfasst von Michael Agrez. Beteiligte Einrichtung: InterK Peptide Therapeutics Limited, North Ryde, New South Wales, Australia michael.agrez@interk.com.au. Hauptthemen laut MEDLINE: Neoplasms, Immune Tolerance, Immunotherapy, Immunologic Surveillance. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maintenance of anticancer immunity without compromising immune tolerance remains a challenge. Immunosuppressive regulatory T cells (Tregs) are the guardians of immune tolerance that underpin prevention of autoimmune responses. Tregs express checkpoint molecules that suppress autoreactive immune cells from being activated by endogenous (self) proteins. However, expression of these checkpoints on immune cells contributes to cancer cell evasion from the immune system while inhibition of checkpoint signaling in cancer immunotherapy induces autoimmune-related adverse events. Two instructive cytokines that regulate the opposing functions of immunosuppressive Tregs and anticancer responses mediated by cytotoxic natural killer cells include the interleukins, IL-2 and IL-12. An overview based on published data is described herein to highlight how manipulation of these cytokines may have dual action in oncologic and autoimmune models. This raises the possibility of exploiting mechanisms in cancer immunotherapy that could promote anticancer immunity while still maintaining immune tolerance. Given the role of peptides in protein-related interactions, it remains important in rational drug design to remain vigilant for potentially beneficial effects that could benefit both cancer surveillance and immune tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune ToleranceImmunotherapyImmunologic SurveillanceHumansAnimalsT-Lymphocytes, Regulatory

Stichwörter der Autor:innen

AutoimmuneCytokineImmune Checkpoint InhibitorImmune related adverse event - irAEImmunotherapy

Autor:innen und Institutionen

  • InterK Peptide Therapeutics Limited, North Ryde, New South Wales, Australia michael.agrez@interk.com.au.

Zitieren

APA

Agrez, M. (2026). Immune tolerance versus cancer surveillance: an ongoing challenge. Journal for ImmunoTherapy of Cancer, 14(5), e014602. https://doi.org/10.1136/jitc-2025-014602

Vancouver

Agrez M. Immune tolerance versus cancer surveillance: an ongoing challenge. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014602. doi:10.1136/jitc-2025-014602

BibTeX
@article{Agrez2026,
  author = {Agrez, Michael},
  title = {Immune tolerance versus cancer surveillance: an ongoing challenge},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {e014602},
  doi = {10.1136/jitc-2025-014602}
}
Kostenlos starten →